What are OncoHaem and OncoHaem PLUS? OncoHaem and OncoHaem PLUS are molecular panels for hematological diseases based on Next-Generation Sequencing (NGS) technology. They are used to identify genetic alterations associated with hematological neoplasms, helping to provide a more detailed characterization of the disease.
What do they analyze? Depending on the panel, different genetic alterations may be analyzed, including:
Mutations in genes that are important for hematological diseases. OncoHaem PLUS may combine DNA analysis with the identification of gene fusions in RNA, providing a broader molecular profile.
Which diseases are they used for? The panels may be useful in the molecular evaluation of diseases such as: Acute leukemias;
NGS panels for hematological neoplasms may assist in diagnosis, classification, prognostic assessment, and treatment guidance.
OncoHaem vs. OncoHaem PLUS OncoHaem focuses on the identification of important molecular alterations in hematological diseases. OncoHaem PLUS provides a broader analysis, including combinations of SNV/Indel alterations and gene fusions, depending on the version of the requested panel.
How is the test performed? Depending on the clinical case and the requested panel, the sample may be peripheral blood or bone marrow. DNA and, when required, RNA are extracted from the sample and analyzed using NGS technology.
Why is it important? Molecular analysis may help the physician with:
OncoHaem is a molecular panel that analyzes genetic alterations associated with various hematological diseases. The analysis is performed using Next-Generation Sequencing (NGS) technology.
OncoHaem PLUS is an expanded panel that may analyze genetic alterations such as SNVs, small indels, and gene fusions, depending on the content of the requested panel.
They may be used for the molecular evaluation of:
Depending on the disease and the requested panel, the sample may be collected from peripheral blood or bone marrow. DNA and, when required, RNA are isolated from the sample and analyzed using NGS technology.
No, fasting is not required for sample collection.
Depending on the panel, the following may be analyzed:
The test result should not be interpreted on its own. Identification of a genetic alteration may have diagnostic or prognostic significance, but its meaning depends on the suspected disease and other clinical findings.
The result may help the physician characterize the disease, assess prognosis, and guide treatment when the identified alterations have clinical significance.
No. This test is part of a broader hematological evaluation. Depending on the case, a complete blood count, immunophenotyping/Flow Cytometry, cytogenetic analysis, bone marrow biopsy, and other molecular tests may be required.
In selected cases, molecular analyses may be used to monitor genetic alterations during disease follow-up. The physician determines whether and when repeat testing is required.
Not necessarily. The selection of the panel depends on the suspected diagnosis, clinical characteristics, and the recommendation of the hematologist/oncologist.
The results should be interpreted by a hematologist or oncologist together with the patient's clinical history, laboratory findings, and results of other tests.
Not every alteration identified in a tumor or hematological disease is hereditary. If the result raises suspicion of an inherited alteration, the physician may recommend genetic counseling and further testing.
